Navigation Links
Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Date:2/13/2008

r extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C- IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1- 800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; legal matters, including the ultimate outcome of the FTC litigation or the amount of time it will take for the FTC litigation to be resolved; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
2. Cephalon General Counsel John E. Osborn to Resign Position
3. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
4. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
5. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Announces Strong Third Quarter Financial Results
9. Cephalon Quarterly Conference Call Invitation
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... WORMS, GERMANY – May 26, ... GRA) announces that its manufacturing facility in Worms, ... from EXCiPACT™, an independent organization that certifies manufacturers, ... , All three Grace facilities that produce its ... gels have now received GMP certification, following the ...
(Date:5/26/2015)... May 26, 2015   Intrexon Corporation (NYSE: ... Gregory Frost , Ph.D., Senior Vice President and Head ... Global Healthcare Conference on Wednesday, June 3 rd , at ... New York City . About Intrexon ... Powering the Bioindustrial Revolution with Better DNA ™ to ...
(Date:5/26/2015)... , May 26, 2015   PDI , ... today announced that Oakwood Healthcare in ... the winning entry in Delivering the ... who display excellence in building collaborative relationships between ... in healthcare facilities.  Oakwood Healthcare,s ...
(Date:5/26/2015)... , May 26, 2015 Mr. Kevin ... family, thanks President Barack Obama and President ... the time of loss of Dr. Rongxiang Xu , ... and a leader ahead of his time, Dr. Xu,s commitment ... community leave a legacy that will not be forgotten. As ...
Breaking Biology Technology:CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Dr. Rongxiang Xu, Beyond A Legend 2
... Board of Directors of the Pittsburgh Life Sciences Greenhouse ... formation and business growth services to the region,s life ... of Peter M. DeComo as the new Chairman of ... will replace Dr. D. Lansing Taylor who is stepping ...
... hair-like blood vessels in the back of our eyes, researchers ... those that bring blood to the heart respond to air ... otherwise healthy people exposed to high levels of air pollution ... of heart disease. Previous studies linked pollution to heart ...
... In 2008, experiments at The Fu Foundation School of ... graphene, a single layer of graphite only one atom ... raised a question for Chris Marianetti, Assistant Professor in ... how and why does graphene break? ...
Cached Biology Technology:The Pittsburgh Life Sciences Greenhouse Announces New Chairman of the Board 2Photos of tiny blood vessels in the eye link air pollution to heart disease 2Columbia engineering team discovers graphene's weakness 2
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... The founder of a public database that helps doctors ... decisions is the 2009 recipient of the March of ... field of genetic sciences. Roberta "Bonnie" Pagon, MD, ... of Medicine in Seattle, developed the Web site genetests.org ...
... have observed the initiation of a mass gathering and subsequent ... case, fish. The work, conducted using a novel imaging ... that vast oceanic fish shoals inhabit," the team writes in ... also confirms theories about the behavior of large groups of ...
... unveiled the evolutionary origin of the different chromosomal ... comprehensive comparison of the Agrobacterium sequence information with ... general model for how second chromosomes are formed ... Rhizobiaceae family, which also includes the benign, nitrogen-fixing ...
Cached Biology News:Roberta A. Pagon receives lifetime award in genetics from March of Dimes 2Team IDs genesis of mass migrations 2Team IDs genesis of mass migrations 3Evolutionary origin of bacterial chromosomes revealed 2
... Ready-to-use liquid controls for monitoring Aldolase ... & abnormal) with targeted manufacturing values ... 20 ± 3 IU/L. 30-day ... at 2-8 C. Level 1: 3 ...
Request Info...
One-step, microplate or cuvet, colorimetric, linear detection range 0.2 mg/dL to 20 mg/dL. Procedure: 20 min....
Recombinant Mouse Noggin...
Biology Products: